Sun Pharma will be promoting and distributing “Axcer®” brand in India. This collaboration enables Astrazeneca to expand usage of this molecule through wider reach to physicians and thereby benefiting a greater number of ACS patients. It strengthens Sun Pharma's cardiology portfolio with the addition of a new patented therapy.